171 related articles for article (PubMed ID: 10999215)
1. Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus.
Ensoli B; Cafaro A
AIDS Clin Rev; 2000-2001; ():23-61. PubMed ID: 10999215
[No Abstract] [Full Text] [Related]
2. Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine.
Das AT; Zhou X; Vink M; Klaver B; Berkhout B
Expert Rev Vaccines; 2002 Oct; 1(3):293-301. PubMed ID: 12901570
[TBL] [Abstract][Full Text] [Related]
3. AIDS vaccine: efficacy, safety and ethics.
Veljkovic V; Veljkovic N; Glisic S; Ho MW
Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
[TBL] [Abstract][Full Text] [Related]
4. The immune response to HIV: implications for vaccine development.
Bolognesi DP
Semin Immunol; 1993 Jun; 5(3):203-14. PubMed ID: 8347841
[TBL] [Abstract][Full Text] [Related]
5. AIDS vaccine development in primate models.
Almond NM; Heeney JL
AIDS; 1998; 12 Suppl A():S133-40. PubMed ID: 9632994
[No Abstract] [Full Text] [Related]
6. Challenges and opportunities for development of an AIDS vaccine.
Nabel GJ
Nature; 2001 Apr; 410(6831):1002-7. PubMed ID: 11309631
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
[TBL] [Abstract][Full Text] [Related]
8. Human versus HIV: round 2 defeat in AIDS vaccine development.
Lu S
Expert Rev Vaccines; 2008 Mar; 7(2):151-3. PubMed ID: 18324884
[No Abstract] [Full Text] [Related]
9. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
[TBL] [Abstract][Full Text] [Related]
10. A review of vaccine research and development: the human immunodeficiency virus (HIV).
Girard MP; Osmanov SK; Kieny MP
Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298
[TBL] [Abstract][Full Text] [Related]
11. HIV/AIDS in China. Vaccine development with a distinctly Chinese flavor.
Cohen J
Science; 2004 Jun; 304(5676):1437. PubMed ID: 15178780
[No Abstract] [Full Text] [Related]
12. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
[TBL] [Abstract][Full Text] [Related]
13. Progress and obstacles in the development of an AIDS vaccine.
Letvin NL
Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
[TBL] [Abstract][Full Text] [Related]
14. Attenuated HIV vaccine: caveats.
Ruprecht RM; Baba TW; Liska V
Science; 1996 Mar; 271(5257):1790-2. PubMed ID: 8596941
[No Abstract] [Full Text] [Related]
15. Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.
Joseph J; Saubi N; Pezzat E; Gatell JM
Expert Rev Vaccines; 2006 Dec; 5(6):827-38. PubMed ID: 17184220
[TBL] [Abstract][Full Text] [Related]
16. HIV vaccines under study.
Ravanfar P; Mendoza N; Satyaprakash A; Jordan BI
Dermatol Ther; 2009; 22(2):158-67. PubMed ID: 19335727
[TBL] [Abstract][Full Text] [Related]
17. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
18. Development of prophylactic AIDS vaccines: the current state of affairs.
Hanke T
Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
[TBL] [Abstract][Full Text] [Related]
19. Diversity considerations in HIV-1 vaccine selection.
Gaschen B; Taylor J; Yusim K; Foley B; Gao F; Lang D; Novitsky V; Haynes B; Hahn BH; Bhattacharya T; Korber B
Science; 2002 Jun; 296(5577):2354-60. PubMed ID: 12089434
[TBL] [Abstract][Full Text] [Related]
20. No vaccine against HIV yet--are we not perfectly equipped?
Singh M
Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]